These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26971191)

  • 41. A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    McKay RR; Werner L; Mostaghel EA; Lis R; Voznesensky O; Zhang Z; Marck BT; Matsumoto AM; Domachevsky L; Zukotynski KA; Bhasin M; Bubley GJ; Montgomery B; Kantoff PW; Balk SP; Taplin ME
    Clin Cancer Res; 2017 Feb; 23(4):935-945. PubMed ID: 27683182
    [No Abstract]   [Full Text] [Related]  

  • 42. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
    BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer.
    Stuyckens K; Saad F; Xu XS; Ryan CJ; Smith MR; Griffin TW; Yu MK; Vermeulen A; Nandy P; Poggesi I
    Clin Pharmacokinet; 2014 Dec; 53(12):1149-60. PubMed ID: 25204404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study.
    Stein CA; Levin R; Given R; Higano CS; Nemeth P; Bosch B; Chapas-Reed J; Dreicer R
    Urol Oncol; 2018 Feb; 36(2):81.e9-81.e16. PubMed ID: 29150328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
    Caffo O; De Giorgi U; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Macrini S; Messina C; Giordano M; Alesini D; Zustovich F; Fraccon AP; Vicario G; Conteduca V; Maines F; Galligioni E
    BJU Int; 2015 May; 115(5):764-71. PubMed ID: 24988879
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.
    Carton E; Noe G; Huillard O; Golmard L; Giroux J; Cessot A; Saidu NE; Peyromaure M; Zerbib M; Narjoz C; Guibourdenche J; Thomas A; Vidal M; Goldwasser F; Blanchet B; Alexandre J
    Eur J Cancer; 2017 Feb; 72():54-61. PubMed ID: 28027516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.
    Liu Y; Long W; Zhang Z; Mai L; Huang S; Liu B; Cao W; Wu J; Zhou F; Li Y; He L
    Radiat Oncol; 2021 Jan; 16(1):5. PubMed ID: 33407637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
    Mostaghel EA; Marck BT; Kolokythas O; Chew F; Yu EY; Schweizer MT; Cheng HH; Kantoff PW; Balk SP; Taplin ME; Sharifi N; Matsumoto AM; Nelson PS; Montgomery RB
    Clin Cancer Res; 2021 Nov; 27(21):6001-6011. PubMed ID: 34407973
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abiraterone acetate + prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients.
    Biró K; Budai B; Szőnyi M; Küronya Z; Gyergyay F; Nagyiványi K; Géczi L
    Urol Oncol; 2018 Feb; 36(2):81.e1-81.e7. PubMed ID: 29153623
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?
    Davies RS; Smith C; Button MR; Tanguay J; Barber J; Palaniappan N; Staffurth J; Lester JF
    Anticancer Res; 2015 Oct; 35(10):5615-21. PubMed ID: 26408734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
    Wang Y; Zhang H; Shen W; He P; Zhou Z
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.
    Van Praet C; Rottey S; Van Hende F; Pelgrims G; Demey W; Van Aelst F; Wynendaele W; Gil T; Schatteman P; Filleul B; Schallier D; Machiels JP; Schrijvers D; Everaert E; D'Hondt L; Werbrouck P; Vermeij J; Mebis J; Clausse M; Rasschaert M; Van Erps J; Verheezen J; Van Haverbeke J; Goeminne JC; Lumen N
    Urol Oncol; 2016 Jun; 34(6):254.e7-254.e13. PubMed ID: 26850781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
    Fizazi K; Chi KN; de Bono JS; Gomella LG; Miller K; Rathkopf DE; Ryan CJ; Scher HI; Shore ND; De Porre P; Londhe A; McGowan T; Pelhivanov N; Charnas R; Todd MB; Montgomery B
    Eur Urol; 2016 Sep; 70(3):438-44. PubMed ID: 26965562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
    Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
    Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.
    Sella A; Sella T; Peer A; Berger R; Frank SJ; Gez E; Sharide D; Hayat H; Hanovich E; Kovel S; Rosenbaum E; Neiman V; Keizman D
    Clin Genitourin Cancer; 2014 Dec; 12(6):428-32. PubMed ID: 25066221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer.
    Boukovala M; Spetsieris N; Weldon JA; Tsikkinis A; Hoang A; Aparicio A; Tu SM; Araujo JC; Zurita AJ; Corn PG; Pagliaro L; Kim J; Wang J; Subudhi SK; Tannir NM; Logothetis CJ; Troncoso P; Wen S; Efstathiou E
    Eur J Cancer; 2020 Mar; 127():67-75. PubMed ID: 31986451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
    Szmulewitz RZ; Peer CJ; Ibraheem A; Martinez E; Kozloff MF; Carthon B; Harvey RD; Fishkin P; Yong WP; Chiong E; Nabhan C; Karrison T; Figg WD; Stadler WM; Ratain MJ
    J Clin Oncol; 2018 May; 36(14):1389-1395. PubMed ID: 29590007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
    Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H
    Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Germline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer.
    Hahn AW; Gill DM; Nussenzveig RH; Poole A; Farnham J; Cannon-Albright L; Agarwal N
    Clin Genitourin Cancer; 2018 Aug; 16(4):288-292. PubMed ID: 29674118
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
    Lorente D; Omlin A; Ferraldeschi R; Pezaro C; Perez R; Mateo J; Altavilla A; Zafeirou Z; Tunariu N; Parker C; Dearnaley D; Gillessen S; de Bono J; Attard G
    Br J Cancer; 2014 Dec; 111(12):2248-53. PubMed ID: 25314055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.